HOME >> BIOLOGY >> NEWS
Smallpox outbreak: How long would it take for vaccines to protect people? Would it work?

ST. LOUIS -- In the event of a smallpox outbreak in the United States, how long would it take for a vaccinSLU scientist leads national studye to start protecting Americans by stimulating an immune response?

A new national study led by Saint Louis University School of Medicine will attempt to answer this question.

General routine vaccinations for smallpox were stopped in the United States in 1971, and the world was declared free of smallpox in 1980. But because of the recent concern about biowarfare and bioterrorism throughout the world, the U.S. government is making efforts to improve its ability to protect its citizens in the event of a bioterrorist attack involving the smallpox virus (Variola major virus).

This study at Saint Louis University will look at the ability of an investigational vaccine made by Bavarian Nordic to stimulate the immune system against smallpox.

"Vaccines prevent disease by giving the body a jump-start at recognizing the infecting virus or bacteria," said Sharon Frey, M.D., the principal investigator for the study at Saint Louis University. "After successful vaccination, the body experiences a quicker fighting response to the infection, which lessens or completely avoids the symptoms of illness."

Unlike some other diseases, getting vaccinated following exposure to smallpox could provide protective effects. For example, for the flu vaccine to work, people need to get vaccinated before being exposed to influenza. The currently licensed smallpox vaccine, however, provides benefits post-exposure, and may be useful in further preventing the spread of the disease.

"If there were a release of the smallpox virus, we would vaccinate people immediately after the release," Frey said. "We'd move in and vaccinate people to prevent the spread."

Frey said this research compares the ability of a new investigational smallpox vaccine called IMVAMUNE to produce a strong immune response
'"/>

Contact: Joe Muehlenkamp
muehlenk@slu.edu
314-977-8015
Saint Louis University
30-Apr-2007


Page: 1 2

Related biology news :

1. AAAS analysis finds Congress would add billions to FY 2008 R&D investment
2. The bee that would be queen
3. 2-protein team would be lost without each other
4. Healthy coastal wetlands would adapt to rising oceans
5. Is it ethical for scientists to do research abroad that would be forbidden at home?
6. Designer babies - what would you do for a healthy baby?
7. New discovery: If it werent for this enzyme, decomposing pesticide would take millennia
8. Proposal would allow wild animals to roam North America
9. Cookbook recipes would cure disease with nontoxic DNA delivery systems
10. Passage of Marin County GMO ban would encourage widespread use of harsh pesticides
11. Passage of GMO ban in San Luis Obispo would encourage use of harsh pesticides

Post Your Comments:
(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
(Date:7/3/2015)... Forskare kan ansöka ... http://www.openinnovationinscience.at till det återkommande utbildningsprogrammet "Lab ... i Wien .  ... forskare och vetenskapsmän som genomfördes av Ludwig ... utmaningar bristen på incitament för att undersöka ...
(Date:7/2/2015)... GLEN ELLYN, Ill. , July 2, 2015 /PRNewswire-USNewswire/ ... and Colton Eakins are gaining invaluable real-world ... Institute of Technology this summer. The students ... Dr. Jeff Wereszczynski,s research group at IIT. ... Professors Dr. Tom Carter , Physics; Dr. ...
(Date:7/1/2015)... ... 2015 , ... It is now possible to separate two common disorders: post-traumatic ... tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, and ... is believed to be the largest brain imaging study ever, will be published on ...
(Date:7/1/2015)... 2015   Neuraltus Pharmaceuticals, Inc. , a privately-held ... drugs to treat neurodegenerative diseases such as amyotrophic ... G. Miller , M.D., Director of the Forbes Norris ... Medical Center in San Francisco, has been awarded a ... to help fund a Phase 2 clinical study ...
Breaking Biology Technology:Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3COD Students Participate in Prestigious Summer Internships 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
Cached News: